An Interview With Leo Ehrlich, Cellceutix CEO [View article]
Logistics, For a good grasp on the potential value of kevetrin, i like this article posted by ajackson a while back. His opinion covers many relevant points and the revenue potential of the cancers kevetrin is being tested on. http://seekingalpha.co...
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Hello olsondavid and me39, Thank you for voicing your thoughts here, i appreciate and respect all opinions, as I would hope others would do for me even if they strongly disagree.. I understand that my opinions about Kevetrin are about as bullish as can be, and it certainly is not a view I expect everyone to have. However, I do want to clarify that although my thoughts are very direct and optimistic, I genuinely believe in the science and the management here. I am a long term investor in Cellceutix, and certainly not interested in any shady attempts at quick profits or "pump and dump" as its called. I am holding this stock because I believe it will be very successful once Kevetrin is fully proven with solid human clinical trial data.
Fortunately for all of us, whether you are the biggest bull on CTIX as I am, or the biggest skeptic as some may be, the good news is that the human trials at Harvard have been dosing for going into 7 months now, and the team at Dana Farber will be doing a poster presentation at the ASCO conference at the end of this month. I do believe at this point and shortly after the facts and the trial data will draw a clear picture of just how Kevetrin is performing. I wish you both the best of luck in whatever choices of investments you pursue. - TP
Which Drug Moves Cellceutix First: Kevetrin Or Prurisol? [View article]
There are many eyes on the Kevetrin trial. Targeting P53 and successfully activating this gene with low toxicity would without a doubt be a breakthrough into the next gen of cancer treatment. Will be very interesting to see trial data and results as the current phase 1 human trial at Harvard now enters its 7th month of dosing advanced stage 4 patients.
This article is more relevant today than ever. We are awaiting the next Phase I clinical trial update from Harvard. The next step is to approve a 4th cohort and elevate dosing. So far, so good with the trial as no Dose Limiting Toxicities have been reported.
There is also a steady buzz speculating about the CEO's recent comments that Dana Farber has decided to initiate P21 biomarker testing so early in the trial. This could potentially signal at a very early stage that Kevetrin is activating P53 in humans as it did in animal studies. Clearly Harvard would not waste it's time testing for P21 unless they believed they had some compelling data to justify it.
Things are about to get very interesting for Cellceutix and it's shareholders. ASCO, the super bowl of oncology, is right around the corner and Cellceutix will be center stage with a poster presentation. Perhaps a big announcement declaring efficacy will follow shortly after?
An Interview With Leo Ehrlich, Cellceutix CEO [View article]
Great interview and article, loaded with lots of very promising and compelling info for current and potential shareholders. This company has so much going on simultaneously that it is almost hard to wrap your head around, but this article and interview did just that.
Which Drug Moves Cellceutix First: Kevetrin Or Prurisol? [View article]
Excellent and timely article, very nicely written! There is a flurry of activity going on right now with Kevetrin trials and studies, but investors should not lose sight of Prurisol and the fact that a trial announcement start date is imminent, and these trial results will comevery rapidly. With the confirmation of proof of concept could come a partnership/licensing deal that will bring significant revenue to Cellceutix as it marches onward in clinical trials at Harvard for Kevetrin.
For those investors willing to build a position now with the stock holding at a mere $2 per share, the risk to reward ratio is in my opinion probably the most compelling in the biotech industry right now.
This could change rapidly, as I anticipate any number of catalysts could send the stock price soaring in the short term: - a Kevetrin clinical trial update and bloodwork analysis - the announcement of a clinical trial agreement with the premiere cancer in the SouthWest - potential announcement of an agreement with the National Cancer Institute and a potential SPORE grant to fund further research and trials - an announcement on planned presentation of Kevetrin data at ASCO - Prurisol clinical trial start date and location - Prurisol manufacturing and production completed along with sending product to the FDA for approval
As you can see, any number of imminent events and developments have the potential to send this undervalued stock up significantly. With the share price holding very steady at $2 with little to no selling, a strong, long shareholder base will ensure that price movement going up will be substantial with any good news.
Great article, well thought through and logical outlook, a pleasure to read a well researched and accurate article. Nice job!
Agree here, this was a huge miss on the part of the NYTimes. Excellent article with thoughtful speculation and detailed info, really a great read for those seeking to find out about the potential of kevetrin.
Q&A: Cellceutix CEO Leo Ehrlich - Future Billion-Dollar Anti-Psoriasis Compound [View article]
Thank you, I felt it would be helpful to lay out the different key elements of the company strategy in a Q&A session. For a small biotech like this, it is almost hard to wrap your head around all the world class institutions and big name connections that are coalescing around the company, as kevetrin and prurisol both advance onwards to potentially improve the lives of millions of people.
Watch Cellceutix Closely For Potential Catalysts In 2013 [View article]
A well thought through and well written article, I agree the potential of this company is incredible, and offers one of the better risk to reward ratios out ere. Nice job!
Why The Aspire Deal Is A Winner For Cellceutix Shareholders [View article]
I agree with bio this is a fantastic write up providing clear, concise, and specific info on why this is a great finance deal for the company. More importantly it builds even more confidence in the ongoing trials as CTIX would not get such a favorable deal if things weren't progressing well on the trial front. Great write up, thanks for sharing your thoughts!
An Interview With Leo Ehrlich, Cellceutix CEO [View article]
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
Thank you for voicing your thoughts here, i appreciate and respect all opinions, as I would hope others would do for me even if they strongly disagree.. I understand that my opinions about Kevetrin are about as bullish as can be, and it certainly is not a view I expect everyone to have. However, I do want to clarify that although my thoughts are very direct and optimistic, I genuinely believe in the science and the management here. I am a long term investor in Cellceutix, and certainly not interested in any shady attempts at quick profits or "pump and dump" as its called. I am holding this stock because I believe it will be very successful once Kevetrin is fully proven with solid human clinical trial data.
Fortunately for all of us, whether you are the biggest bull on CTIX as I am, or the biggest skeptic as some may be, the good news is that the human trials at Harvard have been dosing for going into 7 months now, and the team at Dana Farber will be doing a poster presentation at the ASCO conference at the end of this month. I do believe at this point and shortly after the facts and the trial data will draw a clear picture of just how Kevetrin is performing. I wish you both the best of luck in whatever choices of investments you pursue. - TP
Which Drug Moves Cellceutix First: Kevetrin Or Prurisol? [View article]
Pfizer Eyes Kevetrin? [View article]
There is also a steady buzz speculating about the CEO's recent comments that Dana Farber has decided to initiate P21 biomarker testing so early in the trial. This could potentially signal at a very early stage that Kevetrin is activating P53 in humans as it did in animal studies. Clearly Harvard would not waste it's time testing for P21 unless they believed they had some compelling data to justify it.
Things are about to get very interesting for Cellceutix and it's shareholders. ASCO, the super bowl of oncology, is right around the corner and Cellceutix will be center stage with a poster presentation. Perhaps a big announcement declaring efficacy will follow shortly after?
An Interview With Leo Ehrlich, Cellceutix CEO [View article]
Great job Karin, thank you for sharing!
Which Drug Moves Cellceutix First: Kevetrin Or Prurisol? [View article]
For those investors willing to build a position now with the stock holding at a mere $2 per share, the risk to reward ratio is in my opinion probably the most compelling in the biotech industry right now.
This could change rapidly, as I anticipate any number of catalysts could send the stock price soaring in the short term:
- a Kevetrin clinical trial update and bloodwork analysis
- the announcement of a clinical trial agreement with the premiere cancer in the SouthWest
- potential announcement of an agreement with the National Cancer Institute and a potential SPORE grant to fund further research and trials
- an announcement on planned presentation of Kevetrin data at ASCO
- Prurisol clinical trial start date and location
- Prurisol manufacturing and production completed along with sending product to the FDA for approval
As you can see, any number of imminent events and developments have the potential to send this undervalued stock up significantly. With the share price holding very steady at $2 with little to no selling, a strong, long shareholder base will ensure that price movement going up will be substantial with any good news.
Great article, well thought through and logical outlook, a pleasure to read a well researched and accurate article. Nice job!
The Amazing P53 Race [View article]
Small Pharma Watch List: Week Of January 21st [View article]
The Amazing P53 Race [View article]
Q&A: Cellceutix CEO Leo Ehrlich - Future Billion-Dollar Anti-Psoriasis Compound [View article]
Watch Cellceutix Closely For Potential Catalysts In 2013 [View article]
Why The Aspire Deal Is A Winner For Cellceutix Shareholders [View article]